PARP1 and glioblastoma: Notably, unlike some other PARP inhibitors, pamiparib is not a substrate of P-glycoprotein (P-gp), which enhances its ability to cross the blood–brain barrier (BBB), making it a promising candidate for treating brain tumors, such as glioblastoma [1,9].